Leishmaniasis is a group of diseases with a spectrum of clinical manifestations 
ranging from cutaneous ulcers to visceral leishmaniasis, which results from the 
bite of an infected sandfly to human. Attempts to develop an effective vaccine 
have been shown to be feasible but no vaccine is in active clinical use. This 
study adopts a Reverse Vaccinology approach to identify common vaccine 
candidates from both highly pathogenic species Leishmania major and Leishmania 
infantum. Total proteome of both species were compared to identify common 
proteins, which are further taken for sub-cellular localization and 
transmembrane helices prediction. Plasma membrane proteins having only one 
transmembrane helix were first identified and analyzed which are non-homologous 
in human and mouse in order to avoid molecular mimicry with other proteins. 
Selected proteins were analyzed for their binding efficiency to both major 
histocompatibility complex (MHC) class I and class II alleles. As a result, 19 
potential epitopes are screened in this study using different approaches, which 
can be further verified through in vivo experiments in MHC compatible animal 
models. This study demonstrates that Reverse Vaccinology approach has potential 
in discovering various immunogenic antigens from in silico analysis of 
pathogen's genome or proteome instead of culturing the whole organism by 
conventional methods.